Outlook Therapeutics Inc (NASDAQ:OTLK)’s traded shares stood at 0.38 million during the last session, with the company’s beta value hitting 0.66. At the close of trading, the stock’s price was $6.47, to imply a decrease of -0.31% or -$0.02 in intraday trading. The OTLK share’s 52-week high remains $18.00, putting it -178.21% down since that peak but still an impressive 36.79% since price per share fell to its 52-week low of $4.09. The company has a valuation of $153.08M, with an average of 0.25 million shares in intraday trading volume over the past 10 days and average of 206.31K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Outlook Therapeutics Inc (OTLK), translating to a mean rating of 1.14. Of 5 analyst(s) looking at the stock, 0 analyst(s) give OTLK a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.85.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
After registering a -0.31% downside in the last session, Outlook Therapeutics Inc (OTLK) has traded red over the past five days. The 5-day price performance for the stock is -18.62%, and -11.85% over 30 days. With these gigs, the year-to-date price performance is -17.89%. Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) saw shorts transact 2.43 million shares and set a 16.63 days time to cover.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Looking at statistics comparing Outlook Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Outlook Therapeutics Inc (OTLK) shares are 12.91% up over the last 6 months, with its year-to-date growth rate higher than industry average at 23.96% against 17.20%. Revenue is forecast to grow 15.00% this quarter before falling -18.70% for the next one.
OTLK Dividends
Outlook Therapeutics Inc has its next earnings report out in October. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
Outlook Therapeutics Inc insiders hold 35.83% of total outstanding shares, with institutional holders owning 35.95% of the shares at 56.03% float percentage. In total, 35.95% institutions holds shares in the company, led by ROSALIND ADVISORS, INC.. As of 2024-06-30, the company held over 0.45 million shares (or 3.1534% of shares), all amounting to roughly $3.32 million.
